Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2011-04-26
2011-04-26
Goddard, Laura B (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
Reexamination Certificate
active
07932031
ABSTRACT:
Biomarkers that are useful for identifying a mammal that will respond therapeutically or is responding therapeutically to a method of treating cancer that comprises administering a microtubule-stabilizing agent. In one aspect, the cancer is breast cancer, and the microtubule-stabilizing agent is an epothilone or analog or derivative thereof, or ixabepilone.
REFERENCES:
patent: 5569588 (1996-10-01), Ashby et al.
patent: 2002/0051978 (2002-05-01), Roth et al.
patent: 2003/0166223 (2003-09-01), Sims et al.
patent: WO 93/10121 (1993-05-01), None
patent: WO 98/22461 (1998-05-01), None
patent: WO 98/25929 (1998-06-01), None
patent: WO 99/01124 (1999-01-01), None
patent: WO 99/02514 (1999-01-01), None
patent: WO 99/03848 (1999-01-01), None
patent: WO 99/07692 (1999-02-01), None
patent: WO 99/16416 (1999-04-01), None
patent: WO 99/39694 (1999-08-01), None
patent: WO 99/42602 (1999-08-01), None
patent: WO 99/43320 (1999-09-01), None
patent: WO 00/39276 (2000-07-01), None
patent: WO 00/58254 (2000-10-01), None
patent: WO 00/66589 (2000-11-01), None
patent: WO 01/81342 (2001-11-01), None
patent: WO 02/14323 (2002-02-01), None
patent: WO 02/067941 (2002-09-01), None
patent: WO 02/072085 (2002-09-01), None
patent: WO 02/074042 (2002-09-01), None
patent: WO 02/098868 (2002-12-01), None
patent: WO 03/007924 (2003-01-01), None
patent: WO 03/022844 (2003-03-01), None
patent: WO 03/057217 (2003-07-01), None
patent: WO 03/070170 (2003-08-01), None
patent: WO 03/074053 (2003-09-01), None
patent: WO 03/077903 (2003-09-01), None
patent: WO 03/078411 (2003-09-01), None
patent: WO 03/092683 (2003-11-01), None
patent: WO 03/103712 (2003-12-01), None
patent: WO 2004/014919 (2004-02-01), None
patent: WO 2004/056832 (2004-07-01), None
patent: WO 2004/080458 (2004-09-01), None
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Buzdar et al (Clinical Breast Cancer, 2008, Suppl 2:S71-8).
Baselga et al (J Clinical Oncology, 2009, 27:526-534).
Pusztai (Annals of Oncology, 2007, 18 (Supplement 12): xii15-xii20).
Iwao et al (Cancer, 2000, 89:1732-1738).
Alldridge, L.C. et al., “Annexin 1 regulates cell proliferation by disruption of cell morphology and inhibition of cyclin D1 expression through sustained activation of the ERK1/2 MAPK signal”, Experimental Cell Research, vol. 290, pp. 93-107, 2003.
Allzadeh, A. et al., “Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling”, Nature, vol. 403, pp. 503-511, 2000.
Alon, U. et al., “Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays”, P.N.A.S., vol. 96, pp. 6745-6750, 1999.
Ayers, M. et al., “Gene expression profiles predict complete pathologic response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer”, J. of Clinical Oncology, vol. 22(12), pp. 2284-2293, 2004.
Berti, C. et al., “Mig12, a novel Opitz syndrome gene product partner, is expressed in the embryonic ventral midlines and co-operates with Mid1 to bundle and stabilize microtubules”, BMC Cell Biology, vol. 5(9), pp. 1-12, 2004.
Blanchard, A. P. et al., “Sequence to array: Probing the genome's secrets”, Nature Biotechnology, vol. 14, pp. 1649, 1996.
Bittner, M. et al., “Molecular classification of cutaneous malignant melanoma by gene expression profiling”, Nature, vol. 406, pp. 536-540, 2000.
Bode, C.J. et al., “Epothilone and Paclitaxel: Unexpected Differences in Promoting the Assembly and Stabilization of Yeast Microtubules”, Biochemistry, vol. 41, pp. 3870-3874, 2002.
Chang, J.C. et al., “Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer”, The Lancet, vol. 362, pp. 362-368, 2003.
Cockett, M. et al., “Applied genomics: integration of the technology within pharmaceutical research and development”, Current Opinion in Biotechnology, vol. 11, pp. 602-609, 2000.
David, Della C. et al., “Proteasomal degradation of tau protein”, J. of Neurochemistry, vol. 83, pp. 176-185, 2002.
Dye, R. et al., “Taxol-induced Flexibility of Microtubules and Its Reversal by MAP-2 and Tau*”, The J. of Biological Chemistry, vol. 268(10) pp. 6847-6850, 1993.
Giannakakou, P. et al., “A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells”, PNAS, vol. 97(6), pp. 2904-2909, 2000.
Glinsky, G.V. et al., “Gene expression profiling predicts clinical outcome of prostate cancer”, The J. of Clinical Investigation, vol. 113(6), pp. 913-923, 2004.
Golub, T.R. et al., “Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring”, Science, vol. 286, pp. 531-537, 1999.
Gottesman, M.M. et al., “Multidrug Resistance in Cancer: Role of ATP-Dependent Transporters”, Nature Reviews Cancer, vol. 2, pp. 48-58, 2002.
Hsieh, F.Y. et al., “A Simple Method of Sample Size Calculation for Linear and Logistic Regression”, Statistics in Medicine, vol. 17, pp. 1623-1634, 1998.
Kar, S. et al., “Repeat motifs of tau bind to the insides of microtubules in the absence of taxol”, The EMBO Journal, vol. 22(1), pp. 70-77, 2003.
Khan, J. et al., “Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks”, Nature Medicine, vol. 7(6), pp. 673-679, 2001.
Khan, J. et al., “Gene Expression Profiling of Alveolar Rhabdomyosarcoma with cDNA Microarrays”, Cancer Research, vol. 58, pp. 5009-5013, 1998.
Leonessa, F. et al., “ATP binding cassette transporters and drug resistance in breast cancer”, Endocrine-Related Cancer, vol. 10, pp. 43-73, 2003.
Lockhart, D.J. et al., “Expression monitoring by hybridization to high-density obligonucleotide arrays”, Nature Biotechnology, vol. 14, pp. 1675-1680, 1996.
Rouzier, R. et al., “Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer”, PNAS, vol. 102(23), pp. 8315-8320, 2005.
Sataloff, D.M. et al., “Pathologic response to induction chemotherapy in locally advanced carcinoma of the Breast: A Determinant of Outcome”, J. Am. Coll. Surg., vol. 180, pp. 297-304, 1995.
Schena, M. et al., “Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray”, Science, vol. 270, pp. 467-470, 1995.
Shipp, M.A. et al., “Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning”, Nature Medicine, vol. 8(1), pp. 68-74, 2002.
Sonneveld, P, “Multidrug resistance in haematological malignancies”, J. of Internal Medicine, vol. 247, pp. 521-534, 2000.
Sorlie, T. et al., “Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications”, PNAS, vol. 98(19), pp. 10869-10874, 2001.
Staunton, J.E., “Chemosensitivity prediction by transcriptional profiling”, PNAS, vol. 98(19), pp. 10787-10792, 2001.
Van't Veer, L.J., “Gene expression profiling predicts clinical outcome of breast cancer”, Nature, vol. 415, pp. 530-536, 2002.
Voorhees, P. M. et al., “The Proteasome as a Target for Cancer Therapy”, Clinical Cancer Research, vol. 9, pp. 6316-6325, 2003.
Wagner, P. et al., “Microtubule Associated Protein (MAP)-Tau”, Cell Cycle, vol. 4(9), pp. 1149-1152, 2005.
Wands, J.R. et al., “High Affinity Monoclonal Antibodies to Hepatitis B Surface Antigen (HB,Ag) Produced by Somatic Cell Hybrids”, Gastroenterology, vol. 80, pp. 225-232, 1981.
West, M, et al., “Predicting the clinical status of human breast cancer by using gene expression profiles”. PNAS vol. 98(20), pp. 11462-11467, 2001.
Clopper, C.J. et al., “The use of Confidence or Fiducial Limits Ill
Clark Edwin A.
Lee Hyerim
Shaw Peter
Bristol--Myers Squibb Company
Goddard Laura B
Golian Paul D.
LandOfFree
Methods for determining sensitivity to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for determining sensitivity to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for determining sensitivity to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2714530